レノックスガストー症候群治療薬の世界市場:疫学予測

◆英語タイトル:Lennox Gastaut Syndrome - Epidemiology Forecast to 2030
◆商品コード:DELV20JU210
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年7月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(210名様閲覧)USD3,750 ⇒換算¥397,500見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥596,250見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥795,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Lennox Gastaut Syndrome (LGS) – Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the Lennox Gastaut Syndrome (LGS), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Lennox Gastaut Syndrome (LGS) Disease Understanding

Lennox–Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by the presence of multiple pharmaco-resistant seizure types, including tonic, atypical absences, and tonic or atonic drop attacks, and the presence of electroencephalographic abnormalities, such as slow-spike waves and paroxysmal fast rhythms. Intellectual disability, behavioral and psychiatric disorders are common comorbidities; and these disturbances have multi-factorial pathogenesis.

In addition to the classic seizures, patients with LGS can experience many other seizures, such as myoclonic, focal, and non-convulsive status epilepticus, especially in later stages of the disease. Although intellectual disability (ID) is seen in most patients, nevertheless it can also be absent; therefore, ID is not to be considered as a diagnostic criterion.

Some clinical features, such as cognitive decline, may not be apparent at the onset of the seizures. This makes early diagnosis difficult; however, the syndrome will evolve over a few months to years, and subsequently, all classical features will appear. Tonic seizures, which are the hallmark of the syndrome, may be quite subtle and may only appear during sleep. Moreover, atonic and atypical absence seizures might be difficult to recognize in younger children or may appear later. Myoclonic and partial seizures are less common. Comorbid behavior, sleep, and learning difficulties are also frequently encountered.

Lennox Gastaut Syndrome (LGS) Epidemiology
The Lennox Gastaut Syndrome (LGS) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Lennox Gastaut Syndrome (LGS) epidemiology segmented as the Total Prevalent cases of Lennox Gastaut Syndrome (LGS), Diagnosed Prevalent Cases of Lennox Gastaut Syndrome (LGS), Gender-Specific cases of Lennox Gastaut Syndrome (LGS), Seizure-Specific cases of Lennox Gastaut Syndrome (LGS). The report includes the Prevalent scenario of Lennox Gastaut Syndrome (LGS) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Lennox Gastaut Syndrome (LGS) Epidemiology
The epidemiology segment also provides the Lennox Gastaut Syndrome (LGS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of Lennox Gastaut Syndrome (LGS) Associated in 7MM countries estimated to be 111,798 cases in 2017.

As per the estimates, the United States has the highest Prevalent population of Lennox Gastaut Syndrome (LGS)
Among the EU5 countries, Germany had the highest Prevalent population of Lennox Gastaut Syndrome (LGS). On the other hand, Spain had the lowest Prevalent population with 8,323 cases in 2017.
Scope of the Report
Lennox Gastaut Syndrome (LGS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
Lennox Gastaut Syndrome (LGS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Lennox Gastaut Syndrome (LGS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight about the historical and forecasted patient pool of Lennox Gastaut Syndrome (LGS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
The report helps to recognize the growth opportunities in the 7MM concerning the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Lennox Gastaut Syndrome (LGS)
The report provides the segmentation of the Lennox Gastaut Syndrome (LGS) epidemiology by Prevalent Cases of Lennox Gastaut Syndrome (LGS) in 7MM
The report provides the segmentation of the Lennox Gastaut Syndrome (LGS) epidemiology by Etiology -specific Prevalent Cases of Lennox Gastaut Syndrome (LGS) in 7MM
Report Highlights
11-Year Forecast of Lennox Gastaut Syndrome (LGS) epidemiology
7MM Coverage
Total Prevalent Cases of Lennox Gastaut Syndrome (LGS)
Prevalent Cases according to segmentation: Gender-specific Prevalence of Lennox Gastaut Syndrome (LGS), Seizure-specific Prevalence of Lennox Gastaut Syndrome (LGS)
KOL- Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
What will be the growth opportunities in the 7MM concerning the patient population about Lennox Gastaut Syndrome (LGS)?
What are the key findings of Lennox Gastaut Syndrome (LGS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
What would be the total number of patients of Lennox Gastaut Syndrome (LGS) across the 7MM during the forecast period (2017–2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
What are the disease risk, burden, and unmet needs of Lennox Gastaut Syndrome (LGS)?
What are the currently available treatments for Lennox Gastaut Syndrome (LGS)?
Reasons to buy
The Lennox Gastaut Syndrome (LGS) Epidemiology report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the global Lennox Gastaut Syndrome (LGS) market
Quantify patient populations in the global Lennox Gastaut Syndrome (LGS) market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Lennox Gastaut Syndrome (LGS) therapeutics in each of the markets covered
Understand the magnitude of Lennox Gastaut Syndrome (LGS) population by its Prevalence cases
Understand the magnitude of Lennox Gastaut Syndrome (LGS) population by its Etiology-specific cases
The Lennox Gastaut Syndrome (LGS) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
The Lennox Gastaut Syndrome (LGS) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2017–2030
The epidemiological model in the US is based on the assumption which is based as per Lennox Gastaut Foundation 2016. The organization revealed that there are approximately 14,000-18,000 children with LGS under the age of 18 years in the United States, accounting for about 40% of cases from children, and rest 60% of cases belong to adults.

【レポートの目次】

1. Key Insights

2. Lennox Gastaut Syndrome (LGS): Epidemiology Overview at a Glance

2.1. Patient Share (%) Distribution of LGS in 2017

2.2. Patient Share (%) Distribution of LGS in 2030

3. Executive summary

4. Organizations

5. Disease Overview: Lennox Gastaut Syndrome (LGS)

5.1. Introduction

5.2. Classification

5.3. Signs and Symptoms

5.4. Types of Seizures associated with LGS

5.5. Etiology

5.6. Pathogenesis

5.7. Diagnosis

5.7.1. Differential Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Lennox Gastaut Syndrome (LGS)

6.3. 7MM Total Diagnosed Prevalent Patient Population of Lennox Gastaut Syndrome (LGS)

6.4. Country Wise-Epidemiology of Lennox Gastaut Syndrome (LGS)

6.5. United States

6.5.1. Assumptions and Rationale

6.5.2. Total Prevalent Cases of Lennox Gastaut Syndrome in the United States

6.5.3. Diagnosed Prevalent Cases of Lennox Gastaut Syndrome in the United States

6.5.4. Gender-specific Diagnosed Prevalent Cases of LGS in the United States

6.5.5. Seizure-specific Diagnosed Prevalent Cases of LGS in the United States

6.6. Germany

6.6.1. Assumptions and Rationale

6.6.2. Total Prevalent Cases of Lennox Gastaut Syndrome in Germany

6.6.3. Diagnosed Prevalent Cases of LGS in Germany

6.6.4. Gender-specific Diagnosed Prevalent Cases of LGS in Germany

6.6.5. Seizure-specific Diagnosed Prevalent Cases of LGS in Germany

6.7. France

6.7.1. Assumptions and Rationale

6.7.2. Total Prevalent Cases of Lennox Gastaut Syndrome in France

6.7.3. Diagnosed Prevalent Cases of LGS in France

6.7.4. Gender-specific Diagnosed Prevalent Cases of LGS in France

6.7.5. Seizure-specific Diagnosed Prevalent Cases of LGS in France

6.8. Italy

6.8.1. Assumptions and Rationale

6.8.2. Total Prevalent Cases of Lennox Gastaut Syndrome in Italy

6.8.3. Diagnosed Prevalent Cases of LGS in Italy

6.8.4. Gender-specific Diagnosed Prevalent Cases of LGS in Italy

6.8.5. Seizure-specific Diagnosed Prevalent Cases of LGS in Italy

6.9. Spain

6.9.1. Assumptions and Rationale

6.9.2. Total Prevalent Cases of Lennox Gastaut Syndrome in Spain

6.9.3. Diagnosed Prevalent Cases of LGS in Spain

6.9.4. Gender-specific Diagnosed Prevalent Cases of LGS in Spain

6.9.5. Seizure-specific Diagnosed Prevalent Cases of LGS in Spain

6.10. United Kingdom

6.10.1. Assumptions and Rationale

6.10.2. Total Prevalent Cases of Lennox Gastaut Syndrome in the United Kingdom

6.10.3. Diagnosed Prevalent Cases of LGS in the United Kingdom

6.10.4. Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom

6.10.5. Seizure-specific Diagnosed Prevalent Cases of LGS in the United Kingdom

6.11. Japan

6.11.1. Assumptions and Rationale

6.11.2. Total Prevalent Cases of Lennox Gastaut Syndrome in Japan

6.11.3. Diagnosed Prevalent Cases of LGS in Japan

6.11.4. Gender-specific Diagnosed Prevalent Cases of LGS in Japan

6.11.5. Seizure-specific Diagnosed Prevalent Cases of LGS in Japan

7. Current Treatment Practices

7.1. Treatment Algorithm

7.2. Treatment Guidelines

7.2.1. NICE Guidelines

7.2.2. American Academy of Neurology (AAN)

8. Unmet needs

9. SWOT Analysis

10. Case studies

10.1. Epilepsy in Christianson syndrome: Case of Lennox–Gastaut syndrome

10.2. A Case of Lennox–Gastaut Syndrome in a 6-Year-Old Child with Moyamoya Disease

11. KOL Views

12. Appendix

13. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

Table 1: Features of various epileptic syndromes

Table 2: Genetic tests that might elucidate LGS genetic etiology and diagnosis

Table 3: Total Prevalent Patient Population of LGS in 7MM (2017-2030)

Table 4: Total Diagnosed Prevalent Patient Population of LGS in 7MM (2017-2030)

Table 5: Total Prevalent Cases of LGS in the United States (2017-2030)

Table 6: Total Diagnosed Prevalent Cases of LGS in the United States (2017-2030)

Table 7: Gender-specific Diagnosed Prevalent Cases of LGS in the United States (2017-2030)

Table 8: Seizure-specific Diagnosed Prevalent Cases of LGS in the United States (2017-2030)

Table 9: Total Prevalent Cases of LGS in Germany (2017-2030)

Table 10: Total Diagnosed Prevalent Cases of LGS in Germany (2017-2030)

Table 11: Gender-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2030)

Table 12: Seizure-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2030)

Table 13: Total Prevalent Cases of LGS in France (2017-2030)

Table 14: Total Diagnosed Prevalent Cases of LGS in France (2017-2030)

Table 15: Gender-specific Diagnosed Prevalent Cases of LGS in France (2017-2030)

Table 16: Seizure-specific Diagnosed Prevalent Cases of LGS in France (2017-2030)

Table 17: Total Prevalent Cases of LGS in Italy (2017-2030)

Table 18: Total Diagnosed Prevalent Cases of LGS in Italy (2017-2030)

Table 19: Gender-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2030)

Table 20: Seizure-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2030)

Table 21: Total Prevalent Cases of LGS in Spain (2017-2030)

Table 22: Total Diagnosed Prevalent Cases of LGS in Spain (2017-2030)

Table 23: Gender-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2030)

Table 24: Seizure-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2030)

Table 25: Total Prevalent Cases of LGS in the UK (2017-2030)

Table 26: Total Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2030)

Table 27: Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2030)

Table 28: Seizure-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2030)

Table 29: Total Prevalent Cases of LGS in Japan (2017-2030)

Table 30: Total Diagnosed Prevalent Cases of LGS in Japan (2017-2030)

Table 31: Gender-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2030)

Table 32: Seizure-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2030)

List of Figures

Figure 1: ILAE Classification of Seizure type Basic Version

Figure 2: ILAE Classification of Seizure type Expanded Version

Figure 3: Etiology of LGS

Figure 4: Symptomatic Causes of LGS

Figure 5: Proposed scheme for the pathogenesis of Lennox–Gastaut syndrome based on clinical and experimental data relevant to LGS

Figure 6: Classical diagnostic criteria for LGS

Figure 7: Total Prevalent Patient Population of LGS in 7MM (2017-2030)

Figure 8: Total Diagnosed Prevalent Patient Population of LGS in 7MM (2017-2030)

Figure 9: Total Prevalent Cases of LGS in the United States (2017-2030)

Figure 10: Diagnosed Prevalent Cases of LGS in the United States (2017-2030)

Figure 11: Gender-specific Diagnosed Prevalent Cases of LGS in the United States (2017-2030)

Figure 12: Seizure-specific Diagnosed Prevalent Cases of LGS in the US (2017-2030)

Figure 13: Total Prevalent Cases of LGS in Germany (2017-2030)

Figure 14: Diagnosed Prevalent Cases of LGS in Germany (2017-2030)

Figure 15: Gender-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2030)

Figure 16: Seizure-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2030)

Figure 17: Total Prevalent Cases of LGS in France (2017-2030)

Figure 18: Diagnosed Prevalent Cases of LGS in France (2017-2030)

Figure 19: Gender-specific Diagnosed Prevalent Cases of LGS in France (2017-2030)

Figure 20: Seizure-specific Diagnosed Prevalent Cases of LGS in France (2017-2030)

Figure 21: Total Prevalent Cases of LGS in Italy (2017-2030)

Figure 22: Diagnosed Prevalent Cases of LGS in Italy (2017-2030)

Figure 23: Gender-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2030)

Figure 24: Seizure-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2030)

Figure 25: Total Prevalent Cases of LGS in Spain (2017-2030)

Figure 26: Diagnosed Prevalent Cases of LGS in Spain (2017-2030)

Figure 27: Gender-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2030)

Figure 28: Seizure-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2030)

Figure 29: Total Prevalent Cases of LGS in the UK (2017-2030)

Figure 30: Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2030)

Figure 31: Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2030)

Figure 32: Seizure-specific Diagnosed Prevalent Cases of LGS in the UK (2017-2030)

Figure 33: Total Prevalent Cases of LGS in Japan (2017-2030)

Figure 34: Diagnosed Prevalent Cases of LGS in Japan (2017-2030)

Figure 35: Gender-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2030)

Figure 36: Seizure-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2030)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[レノックスガストー症候群治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆